Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease ...

Corcept Therapeutics' stock surged over 80% after its Phase 3 ROSELLA trial met its primary goal. See why we still consider ...

Moderna stock dips 10% amid FDA resignation, signaling regulatory risks. Strong cash reserves can't offset competitive and ...

Almost £8bn has been wiped off the value of the world’s biggest drugmakers after America’s leading vaccine official was ...

Brace! That’s the only word needed to sum up the feeling around the globe today as everyone gears up for Trump’s Reshape the ...

Over the past year, the screen’s 2024 60-stock portfolio delivered an aggregate total return of 10.6 per cent. That was 6.7 ...

In a welcome move, GSK ADR saw its Relative Strength Rating improve from 69 to 75 on Monday. Please watch the video at ...